ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.001,60
0,54%
S&P 500
5.127,79
1,26%
Dow Jones
38.675,68
1,18%
Euro vs US Dollar
1,07725
-0,01%
Bitcoin
64.145,37
2,00%
Registration Strip Icon for monitor Überwachen Sie mehrere Echtzeitkurse von führenden Börsen wie NASDAQ, NYSE, AMEX, Bovespa und mehr.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. Replimune Group Inc (REPL)

  7. Replimune Group Inc (REPL) News

REPL Replimune Group Inc

6,95
0,39 (5,95%)
04 Mai 2024 - Geschlossen
Verzögert um 15 Minuten
Name Symbol Markt Aktientyp
Replimune Group Inc REPL NASDAQ Common Stock
  Änderung Änderung % Aktuell Zeit
Upgrade Icon
0,39 5,95% 6,95 02:00:00
Handelsbeginn Niedrig Hoch Schlusskurs Handelsende
6,80 6,605 7,08 6,95 6,56
more quote information »

Aktuelle News

Datum Zeit Quelle Überschrift
07.4.202423:00GLOBEInterim Results from the ARTACUS Clinical Trial of RP1..
04.4.202414:00GLOBEReplimune Announces Inducement Grants Under Nasdaq Listing..
26.3.202412:30GLOBEReplimune Announces Appointment of Sushil Patel to CEO and..
06.3.202414:00GLOBEReplimune to Present at the American Association for Cancer..
05.3.202414:00GLOBEReplimune to Present at Three Upcoming Investor Conferences
14.2.202413:21EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
08.2.202414:09EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
08.2.202414:05EDGAR2Form 8-K - Current report
08.2.202414:00GLOBEReplimune Reports Fiscal Third Quarter 2024 Financial..
16.1.202410:06PRNUSDISCO Pharmaceuticals launches as the surfaceome company..
16.1.202409:59PRNUSDISCO Pharmaceuticals launches as the surfaceome company..
08.1.202414:00EDGAR2Form 8-K - Current report
28.12.202314:00GLOBEReplimune to Present at the 42nd Annual J.P. Morgan..
26.12.202323:15EDGAR2Form 8-K - Current report
05.12.202313:19EDGAR2Form 8-K - Current report
05.12.202313:00GLOBEReplimune Shares Initial Primary Analysis Results from..
18.11.202302:01EDGAR2Form 4 - Statement of changes in beneficial ownership of..
18.11.202302:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08.11.202315:10GLOBEReplimune Presents Updated Data on RP2 in Uveal Melanoma..
07.11.202323:03EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
07.11.202314:15EDGAR2Form 8-K - Current report
07.11.202314:00GLOBEReplimune Reports Fiscal Second Quarter 2024 Financial..
04.11.202300:30GLOBEReplimune Presents Updated Interim Results from the ARTACUS..
21.9.202302:04EDGAR2Form 4 - Statement of changes in beneficial ownership of..
21.9.202302:03EDGAR2Form 3 - Initial statement of beneficial ownership of..
19.9.202322:01GLOBEReplimune Announces Inducement Grants Under Nasdaq Listing..
19.9.202314:15EDGAR2Form 8-K - Current report
19.9.202314:00GLOBEReplimune Announces Appointment of Emily Hill as Chief..
14.9.202303:02EDGAR2Form 4 - Statement of changes in beneficial ownership of..
07.9.202315:17EDGAR2Form 8-K - Current report
25.8.202302:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
16.8.202302:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03.8.202315:04EDGAR2Form 8-K - Current report
03.8.202314:45EDGAR2Form S-3ASR - Automatic shelf registration statement of..
03.8.202314:11EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
03.8.202314:09EDGAR2Form 8-K - Current report
03.8.202314:00GLOBEReplimune Reports Fiscal First Quarter 2024 Financial..
01.8.202314:00GLOBEReplimune to Present at Two Upcoming Investor Conferences
31.7.202322:01BWReplimune and Incyte Enter into Clinical Trial Collaboration..
27.7.202302:00EDGAR2Form 3 - Initial statement of beneficial ownership of..
26.7.202323:08EDGAR2Form ARS - Annual Report to Security Holders
26.7.202323:06EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
26.7.202323:02EDGAR2Form DEF 14A - Other definitive proxy statements
20.7.202314:56EDGAR2Form 8-K - Current report
20.7.202314:00GLOBEReplimune Announces Sander Slootweg will Depart from its..
12.7.202303:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
10.7.202322:27EDGAR2Form 144 - Report of proposed sale of securities
06.6.202316:00GLOBEReplimune Presents Initial RP1 Data from the ARTACUS..
05.6.202314:00GLOBEReplimune Appoints Veleka R. Peeples-Dyer to its Board of..
03.6.202320:15GLOBEReplimune Presents RP1 Data from the IGNYTE anti-PD1 Failed..

Kürzlich von Ihnen besucht

NASDAQ
REPL
Replimune
Delayed Upgrade Clock
ADVFN Logo

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten